Fox Business - The Power to Prosper
Search Site

Wednesday, April 7, 2010 as of 11:14 AM ET

Regeneron Pharmaceuticals

    Regeneron is a biotechnology company headquartered in Tarrytown, in New York, US The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities (thus the name), it branched out into the study of both cytokine and tyrosine kinase receptors.

    Read More at Wikipedia ›

    Related Topics

    1. Pharmaceuticals
    2. Watson Pharmaceuticals
    3. Vertex Pharmaceuticals
    4. Amylin Pharmaceuticals
    5. Sanofi S.A.
    6. Bayer AG
    Get updates on Regeneron Pharmaceuticals
    FDA: Regeneron Drug Offers 'Small' Benefit In Gout

    The U.

    S. Food and Drug Administration said that the treatment effect from a proposed Regeneron Pharmaceuticals Inc. (REGN) treatment for gout was "small," and the agency raised concerns that the product might increase the risk for cancer.Regeneron is seeking FDA approval for short-term use of a drug called Arcalyst to treat gout, a form of arthritis. Arcalyst, also known by its generic name rilonacept, is already on the market to treat a rare disease called Cryopyrin-Associated Periodic Syndromes.The product is an injection that is designed to block a protein called interleukin-1, which is secreted by infection-fighting cells in the body. Too much interleukin-1 can be harmful and is linked with several inflammatory diseases, including gout. But many drugs that block proteins in the body can also increase the risk of serious infections and possibly cancer. The FDA has so far refused to approve a similar drug, Ilaris, from Novartis AG (NVS, NOVN.VX) that Novartis has proposed to use as a...

    Read More ›

    1. Bayer Gets Australia Approval For VEGF Trap-Eye Treatment

      German pharmaceutical company Bayer AG (BAYN.XE) said Thursday it received approval for VEGF Trap-Eye, or Eylea, for treatment of patients with wet age-related macul...

    2. Regeneron Loss Widens But Eylea Forecast Is Raised

      Regeneron Pharmaceuticals Inc. (REGN) said sales of its new eye-disease treatment were off to a fast start, causing the company to boost its 2012 sales forecast for ...

    3. Regeneron Jumps 12% On Sales Outlook

      Shares of Regeneron Pharmaceuticals Inc. jumped 12% to $114.10 in early trading Monday after the biotech group raised the sales forecast for its new ophthalmology dr...

    4. Regeneron Jumps 8% On Analyst Upgrade

      Shares of biotech group Regeneron Inc. jumped 8% to $65.89 on Friday following an upgrade by Jefferies & Co. The analysts raised their rating of the stock to buy fro...

    5. Regeneron Up 10% On FDA Approval

      Shares of Regeneron Pharmaceuticals Inc. were up 10% Monday after the U.S. Food and Drug Administration approved the company's Eylea drug, used to treat blindness in...

    6. Regeneron Eye Drug Deemed Safe by Panel

      A new eye medicine from Regeneron Pharmaceuticals and Bayer AG was a safe and effective way of treating vision loss from macular degeneration, a U.S. advisory panel ...

    7. Sanofi, Regeneron Cancer Drug Posts Optimistic Results

      Drugmakers Sanofi-Aventis (NYSE:SNY) and Regeneron Pharmaceuticals (NASDAQ:REGN) said Monday that their investigational cancer drug Zaltrap led to longer survival of...

    8. Bayer, Regeneron To Begin Phase III Trial For VEGF Trap-Eye

      FRANKFURT -(Dow Jones)- German chemical and pharmaceutical company Bayer AG (BAYN.XE) and Regeneron Pharmaceuticals Inc. (REGN) will start a clinical Phase III trial...

    9. Trials of New Painkiller Halted by FDA Over Concern of Joint Damage

      Clinical trails by Johnson & Johnson (NYSE:JNJ), AstraZeneca (NYSE:AZN) and other drug makers studying a new painkiller have been halted due to concerns those drugs ...

    10. Regeneron Pharmaceuticals Ups Shares in Public Offering

      Regeneron Pharmaceuticals (NASDAQ:REGN) increased on Friday the size of its day-earlier common stock offering by one million shares.The company will now publicly off...

    11. UPDATE 2-Astellas Q1 profit down, outlook slashed

      * April-June recurring profit down 18.2 pct* Annual profit forecast cut to 136 bln yen from 155 bln yen* New forecast short of analyst consensus* Says likely to cut ...

    12. UPDATE 1-Astellas Q1 profit down, outlook slashed

      * April-June recurring profit down 18.2 pct* Annual profit forecast cut to 136 bln yen from 155 bln yen* New forecast short of analyst consensus* New forecast does n...

    1. Equinix, Watson Pharmaceuticals Among Stocks Hitting 52-Week Highs Thursday

      These stocks set one-year highs:While trading on above-average volume, Equinix (NASDAQ:EQIX) climbed today, reaching and then surpassing its previous 52-week high of...

    2. Equinix, Watson Pharmaceuticals Among Stocks Up on High Volume Thursday

      Here are stocks that are up on high volume:Today, Equinix (NASDAQ:EQIX) is up on high volume, trading at a volume of 3.1 million, or 3.7 times its average daily volu...

    3. Equinix, Regeneron Pharmaceuticals Among Stocks Gapping Up Thursday

      Here are stocks that gapped up today with opening prices significantly higher than the close on the previous trading day:Equinix (NASDAQ:EQIX) gapped up today, openi...

    4. TIP SHEET: Janus Fund Tries To Manage Risk Of Drug Stocks

      (This article was originally published Wednesday.)--Janus Global Life Sciences fund has year-to-date return of 14.62%--Manager tries to limit exposure to volatility ...

    5. ACE, Tata Motors, Other Stocks Hit 52-Week Highs Thursday

      These are the nine most popular stocks that rose to 52-week highs:The share price of ACE (NYSE:ACE) rose today, reaching and then surpassing its previous 52-week hig...

    6. Sanofi Drug Lowered Cholesterol Levels In Study

      An experimental drug co-developed by Regeneron Pharmaceuticals Inc. (REGN) and Sanofi SA (SAN.FR) reduced levels of so-called "bad" cholesterol by 40% to 72% in pati...

    7. FDA Panel Considers Development Of Pfizer, J&J, Regeneron Pain Drugs

      A federal advisory panel is set to make recommendations Monday on whether a class of experimental arthritis-pain drugs from Pfizer Inc. (PFE) and other companies sho...

    Freebase CC-BY
    Source: Regeneron Pharmaceuticals on Freebase, licensed under CC-BY
    Other content from Wikipedia, licensed under the GFDL